Public RelationsBiond Biologics Announces a Joint Research Publication With Sanofi in the Journal for ImmunoTherapy of Cancer, "BND-22, a First-In-Class Humanized ILT2-Blocking Antibody, Promotes Antitumor Immunity and Tumor Regression" September 14, 2022Biond Biologics Announces a Joint Poster Presentation With Sanofi at The ASCO 2022 Annual Meeting Presenting Pre-Clinical Translational Data of SAR444881 (BND-22)May 31, 2022Biond Biologics Announces First Patients Dosed with BND-22 (SAR444881) Combinations in Phase 1 Clinical TrialMay 23, 2022Biond Biologics Announces Oral Presentation for BND-67, an Inhibitor of CD28 Shedding, a Potential Novel Resistance Mechanism to Anti PD-1 Therapy, at the American Association for Cancer Research (AACR) 2022 Annual MeetingMarch 21, 2022Biond Biologics Announces Closing of $15 Million Series C FinancingNovember 3, 2021Biond Biologics Announces First Patient Dosed in Phase 1 Clinical Trial of BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 ReceptorApril 26, 2021Biond Biologics Announces Global Licensing Agreement with Sanofi for BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 ReceptorJanuary 12, 2021Biond Biologics Announces Poster Presentations at AACR 2020 Virtual Annual MeetingJune 9, 2020Biond Biologics Appoints Jerome Zeldis, M.D., Ph.D., Former Chief Medical Officer of Celgene, to Board of Directors and Provides Corporate UpdateJune 1, 2020Biond Biologics Appoints Immunotherapy Pioneer Alan Korman Ph.D. to Scientific Advisory BoardNovember 25, 2019Biond Biologics Annual Company Gathering | Misgav Industrial ParkMay 12, 2019Biond Biologics Announces $17 Million FinancingJanuary 8, 2019
